Clinical Trial

Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX

Study acronym: LTFU

Terminated

View on ClinicalTrials.gov →

Why the trial stopped

Sangamo declared Chapter 11 Bankruptcy on 23Jun2026 and terminated the study on 21Jul2026.

Summary

Long-term follow-up of subjects who received SB-318, SB-913, or SB-FIX in a previous trial and completed at least 52 weeks post-infusion follow-up in their primary protocol. Enrolled subjects will be followed for a total of up to 10 years following exposure to SB-318, SB-913, or SB-FIX.

Protocol Amendment History 4 changes

critical Trial terminated 2026-08-14

critical Trial terminated: Sangamo declared Chapter 11 Bankruptcy on 23Jun2026 and terminated the study on 21Jul2026. 2026-08-14

notable Primary completion moved earlier: 2030-01-01 -> 2026-06-17 2026-08-14

minor Completion moved earlier: 2030-01-01 -> 2026-06-17 2026-08-14

Trial Details

NCT Number	NCT04628871
Lead Sponsor	Sangamo Therapeutics
Conditions	Hemophilia B, Mucopolysaccharidosis I, Mucopolysaccharidosis II
Enrollment	13 participants
Start Date	2020-11-03
Primary Completion	2026-06-17 (estimated)
Study Completion	2026-06-17 (estimated)
Updated on ClinicalTrials.gov	2026-08-13